Compare · RVMD vs TECX
RVMD vs TECX
Side-by-side comparison of Revolution Medicines Inc. (RVMD) and Tectonic Therapeutic Inc. (TECX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVMD and TECX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $40.57B, about 97.4x TECX ($416.4M).
- Over the past year, RVMD is up 229.0% and TECX is up 19.9% - RVMD leads by 209.2 points.
- RVMD has been more active in the news (12 items in the past 4 weeks vs 8 for TECX).
- RVMD has more recent analyst coverage (25 ratings vs 12 for TECX).
- Company
- Revolution Medicines Inc.
- Tectonic Therapeutic Inc.
- Price
- -
- -
- Market cap
- $40.57B
- $416.4M
- 1M return
- -9.54%
- -24.09%
- 1Y return
- +229.03%
- +19.86%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2018
- News (4w)
- 12
- 8
- Recent ratings
- 25
- 12
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest RVMD
- William Blair initiated coverage on Revolution Medicines
- Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- SEC Form 8-K filed by Revolution Medicines Inc.
- Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
- Chief Development Officer Sandler Alan B. exercised 6,000 shares at a strike of $58.84 and sold $1,275,294 worth of shares (6,309 units at $202.14) as part of a pre-agreed trading plan, decreasing direct ownership by 0.58% to 52,559 units (SEC Form 4)
- SVP & General Counsel Cislini Jeff sold $158,600 worth of shares (765 units at $207.32) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 51,776 units (SEC Form 4)
- Officer Mancini Anthony sold $743,285 worth of shares (3,708 units at $200.45) as part of a pre-agreed trading plan and exercised 3,121 shares at a strike of $33.62, decreasing direct ownership by 1% to 39,765 units (SEC Form 4)
- KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
- Director Anderson Elizabeth M exercised 5,070 shares at a strike of $1.12 and sold $1,958,016 worth of shares (10,143 units at $193.04) as part of a pre-agreed trading plan, decreasing direct ownership by 54% to 4,333 units (SEC Form 4)
Latest TECX
- UBS initiated coverage on Tectonic Therapeutic with a new price target
- Chief Financial Officer Lochner Daniel covered exercise/tax liability with 520 shares, decreasing direct ownership by 0.89% to 58,024 units (SEC Form 4) to cover taxes
- Chief Scientific Officer Mcnamara Peter covered exercise/tax liability with 444 shares and sold $12,349 worth of shares (536 units at $23.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 54,305 units (SEC Form 4) to cover withholding tax
- Chief Medical Officer Ruddy Marcella K. covered exercise/tax liability with 525 shares, decreasing direct ownership by 0.78% to 67,157 units (SEC Form 4) to satisfy withholding tax
- Chief Executive Officer Reicin Alise covered exercise/tax liability with 1,545 shares, decreasing direct ownership by 0.50% to 309,078 units (SEC Form 4) (for withholding tax)
- Chief Business Officer Schwabish Marc covered exercise/tax liability with 411 shares, decreasing direct ownership by 0.91% to 44,903 units (SEC Form 4) (withholding obligation)
- SEC Form 8-K filed by Tectonic Therapeutic Inc.
- Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
- SEC Form 4 filed by Chief Executive Officer Reicin Alise
- SEC Form 4 filed by Chief Medical Officer Ruddy Marcella K.